|Slideshows|December 1, 2020

The 2020 Race Between the Psychiatric Turtle and the Climate Hare

Although our 2020 Presidential race is apparently over, our climate race has no end in sight. Can this race be like the parable where the turtle caught the hare?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Should Solitude Be a Psychiatric Value?

ByRonald W. Pies, MD

October 23rd 2025

Preliminary Report on Dangers of AI Chatbots

ByAllen Frances, MD,Luciana Ramos

October 7th 2025

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 1st 2025

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

ByDaniel Morehead, MD

September 18th 2025

No, Antidepressants Do Not Provoke Mass Shootings

ByJames L. Knoll IV, MD,Ronald W. Pies, MD

September 12th 2025

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The 2020 Race Between the Psychiatric Turtle and the Climate Hare

Newsletter

Related Content

Should Solitude Be a Psychiatric Value?

Preliminary Report on Dangers of AI Chatbots

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

No, Antidepressants Do Not Provoke Mass Shootings

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

The Spiritual Determinants of Health and Mental Health

Caplyta FDA Approval: Benefits for Patients, With Roger McIntyre, MD

Bridging the Categorical-Dimensional Divide: Exploring the PRiSM Diagnostic Instrument

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach